José Biller, MD, FACP, FAAN, FAHA
Journal of Stroke and Cerebrovascular Diseases
Loyola University Chicago
Stritch School of Medicine
Department of Neurology, Bldg. 105
2160 S. 1st Avenue
Maywood, IL 60153
Kazuo Kitagawa, MD, PhD
The Japan Stroke Society
Professor and Chairman
Department of Neurology
Tokyo Women's Medical University
8-1 Kawada-cho, Shinjuku-ku
Tokyo 162-8666 Japan
The Journal of Stroke and Cerebrovascular Diseases now uses a web-based online manuscript submission and review system. Please go to http://ees.elsevier.com/jscvdto submit your manuscript electronically. The website guides authors stepwise through the creation and uploading of the various files.All correspondence, including the Editor's decision and request for revisions, will be by e-mail. Authors may send queries concerning the submission process, manuscript status, or journal procedures to the Editorial Office at firstname.lastname@example.org. Authors unable to submit an electronic version should contact the Editorial Office to discuss alternatives. Authors must guarantee that once their material has been accepted for publication by the Journal, they will not submit the same material or portions thereof to another journal before publication in the Journal of Stroke and Cerebrovascular Diseases.
Any manuscripts determined to be improperly prepared or edited can be returned to the authors without review.All authors should adhere to the following instructions for submission of manuscripts to the Journal of Stroke and Cerebrovascular Diseases.
The author(s) should provide the aforementioned written assurances. In addition, author(s) are welcomed to suggest three to five referees for their paper (please include e-mail addresses). However, the Editors cannot guarantee assignment of a particular reviewer to a paper. Any unusual circumstances surrounding the research or explanations for deviations from standard procedures or format should be explained in the cover letter.
Authors should submit manuscripts electronically, uploading documents to the submission website (http://ees.elsevier.com/jscvd ). The system will convert documents to PDF files. Authors are encouraged to submit manuscripts in Microsoft Word.
The Author Agreement form (pdf) must accompany all submissions. Please scan the signed form and upload it with your online submission.Abbreviations
When using abbreviations, write the full name of the abbreviated item followed by the abbreviation in parentheses at the point of first mention within the body of the manuscript. Do not use abbreviations in the abstract or title of the manuscript.
The title page should contain the following information: (1) The full title of the manuscript, not to exceed 120 characters. (2) The full names of all authors. Authors should be limited to those individuals who contributed in an important manner to the study design, data collection and analysis, or writing of the paper. (3) The department and institution where work was performed, as well as the affiliations of the individual authors. (4) Grant support. (5) Name, address, and phone and fax numbers, and e-mail address of the author to whom communications regarding the manuscript should be directed. (6) A shortened version of the title that is 45 characters or less to be used as a running title.
The abstract is limited to 250 words. Do not use abbreviations, footnotes, or references in the body of the abstract. Include a brief description of the goal, materials and methods, findings, and conclusion of the study.
Introduction, materials and methods, results, and discussion
Include within the body of the text a description of the ethical guidelines that were followed for human and animal studies. If appropriate, provide citation of institutional review by human or animal research committees. Also describe any hazardous procedures or chemicals involved in the studies and what precautions were taken to avoid injury to subjects or investigators. Within the Materials and Methods section, provide a brief but complete description of the statistical methods used, including which tests were used for analysis of which variables. Drugs, medications, or other material should be listed as generic items. If brand names are used, they should be placed after the generic name in parentheses with the manufacturer's name, city, and state or country.
Cite references in text in order of appearance using Arabic numerals in parentheses for citations. Place the reference list at the end of the final text page. References should be listed in text citation number order and must be double spaced. Include the names of all authors up to a total of three before resorting to the use of "et al." All published material, including brief communications and letters to the editor, must be cited in the References section. References to unpublished material, such as personal communications and unpublished data, must be placed within the text and not cited in the References section. Personal communications and unpublished data must include the individual's name, location, and month and year of communication as appropriate. In the reference list, use only abbreviations approved for use in the latest edition of Index Medicus and conform style and punctuation to the requirements listed below:
Bontia R, Ford MA, Stewart AW. Predicting survival after stroke: A three-year follow-up. Stroke 1988;19:669-673.Book chapter:
Whyte J, Robinson KM. Pharmacologic management. In: Glenn MB, Whyte J, eds. The practical management of spasticity in children and adults. Philadelphia: Lea & Febiger, 1990:201-226.Complete book:
Brooks VB. The neural basis of motor control. New York: Oxford University Press, 1986.Special type of article:
Schmidt R, Fazekas F, Horner S, et al. Lipoprotein (a) serum levels of normals are not associated with carotid atherosclerosis and microangiopathy-related cerebral damage. J Stroke Cerebrovasc Dis 1995;5:116 (abstr).Tables
Tables must be cited in text and numbered according to order of appearance. Explanatory matter and source notations for borrowed or adapted tables should be placed in a table footnote, not in the title or table body.
Figure legends should allow interpretation of the figures without reference to the text.
Figures—All figures must be cited in the text and numbered in order of appearance. Computer-generated figures should use solid fills or cross-hatching, not tonal shading. Figure legends should be presented separately and placed in the manuscript after the list of references. Figure legends should be brief and not repetitive of description in the text. Color figures may be accepted but any cost related to reproduction is the responsibility of the author. However, color figures may be published in the electronic version of The Journal at no cost to the authors. Authors should consult Elsevier's website for guidelines for preparing electronic artwork: http://www.elsevier.com/artworkinstructions
Special sections in the Journal of Stroke and Cerebrovascular Diseases
Controversies: A Controversies Section will appear several times yearly and serve as a medium for communicating controversy in the field of stroke and cerebrovascular disease. Authors will be selected for their expertise or outspoken positions or for their objectivity and analysis of a chosen subject. The Editor of the Controversy Section will oversee the preparation of the submitted manuscripts. They or an invited Guest Editor will add their commentary.
Case Reports: Reports of clinical interest should contain no more than 400 words of text and one table or figure. The reference list should be limited to 10. The authors should also limit their case reports to new materials, rare clinical conditions, or cases that provide insight into controversial disease states. They should provide their reason for the case report in a separate cover letter to the author.Journal Club: Journal Club will appear several times yearly. This section provides the opportunity for authors to publish journal clubs conducted in their own institutions on articles of recent interest from peer-reviewed medical literature. The authors should review no more than two articles and provide a summary of each article. This should be followed by their critical review of the paper, followed by the voiced opinion of named commentators in the audience. The authors should then summarize their conclusions at the end of the article. This section provides an opportunity for residents in training and students of clinical cerebrovascular disease to communicate their opinions of the stroke literature.
Methodologic and Technical Reports: The Journal will accept the full description of clinical trials prior to publication of results. The paper must include comprehensive details of the methodologic design. Publications are expected to enhance the science of clinical trials design and to provide extensive detail of these methods. It is hoped that authors will follow up with publication of some, if not, all aspects of the results of the clinical trial.The Technical Note section will permit publication of innovative techniques in neurology, neurosurgery, and interventional radiology as regards the stroke and cerebrovascular disease sciences. The techniques should be novel and extensively described.
Every issue will be introduced by a section in which Guest Editors will comment on papers in the current Journal. These articles will be summarized, highlighting items of special interest. The commentary will discuss the importance of the paper and its relevance to the field. Controversial aspects of the selected articles will be emphasized.
The Journal of Stroke and Cerebrovascular Diseases considers research and publication misconduct to be a serious breach of ethics, and will take such actions as necessary to address such misconduct. Authors should refer to the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors for full information. Authors are also encouraged to visit Elsevier's Ethical Guidelines for Journal Publication.
Plagiarism and duplicate submission are serious acts of misconduct. Plagiarism is defined as unreferenced use of published or unauthorized use of unpublished ideas, and may occur at any stage of planning, researching, writing, or publication. Plagiarism takes many forms, from 'passing off' another's paper as the author's own paper, to copying or paraphrasing substantial parts of another's paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Duplicate submission/publication occurs when two or more papers, without full cross-reference, share the same hypothesis, data, discussion points, or conclusions.NIH Public Access Policy Compliance
To comply with the NIH Public Access Policy, Elsevier will deposit to PubMed Central (PMC) author manuscripts on behalf of authors reporting NIH funded research. The NIH policy requires that NIH-funded authors submit to PubMed Central (PMC), or have submitted on their behalf, their peer-reviewed author manuscripts, to appear on PMC no later than 12 months after final publication. Elsevier will send to PMC the final peer-reviewed manuscript, which was accepted for publication and sent to Elsevier's production department, and that reflects any author-agreed changes made in response to peer-review comments. Elsevier will authorize the author manuscript's public access posting 12 months after final publication. Following the deposit by Elsevier, authors will receive further communications from the NIH with respect to the submission.
Note: Authors must declare their NIH funding (or the other funding bodies listed below) when completing the copyright transfer form.Other Funding Body Policies
Elsevier has also worked with the following funding bodies to ensure that our authors can comply with their policies:
- - Arthritis Research Campaign (UK)
- British Heart Foundation (UK)
- Cancer Research (UK)
- Chief Scientist Office
- Department of Health (UK)
- Howard Hughes Medical Institute (US)
- Medical Research Council (UK)
- Wellcome Trust (UK)
For full details on how these policies are implemented, please see complete information at: http://www.elsevier.com/wps/find/authorsview.authors/fundingbodyagreementsUpdated March 2011Open access
This journal offers you the option of making your article freely available to all via the ScienceDirect platform. To prevent any conflict of interest, you can only make this choice after receiving notification that your article has been accepted for publication. The fee of $3,000 excludes taxes and other potential author fees such as color charges. In some cases, institutions and funding bodies have entered into agreement with Elsevier to meet these fees on behalf of their authors. Details of these agreements are available at http://www.elsevier.com/fundingbodies. Authors of accepted articles, who wish to take advantage of this option, should complete and submit the order form (available at http://www.elsevier.com/locate/openaccessform.pdf). Whatever access option you choose, you retain many rights as an author, including the right to post a revised personal version of your article on your own website. More information can be found here: http://www.elsevier.com/authorsrights.